In the second of a two-part series, Dafna Gladman, Philip Mease, and Oliver FitzGerald discuss the implications and limitations of the recent ACR–NPF guidelines for the management of psoriatic arthritis, together with key clinical trials that have been published since the guidelines were released.
Podden och tillhörande omslagsbild på den här sidan tillhör
Springer Healthcare. Innehållet i podden är skapat av Springer Healthcare och inte av,
eller tillsammans med, Poddtoppen.
